Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is an experimental small molecule belonging to the class of organic compounds known as 2,3-diphenylfurans. It has a molecular formula of C20H17N3O2 and a molecular weight of approximately 331.37 g/mol. The compound has been studied as an inhibitor of serine/threonine-protein kinase Chk1 (checkpoint kinase 1), which plays a key role in cell cycle regulation and DNA damage response pathways. There are no approved indications or clinical trials beyond preclinical/experimental studies for this molecule. Its mechanism involves binding to Chk1 with moderate affinity (IC50 ~20.9 μM), potentially interfering with cell cycle progression and DNA repair processes by inhibiting Chk1 activity[1][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]ethanol.